Literature DB >> 21830446

Rapamycin inhibits the proliferation and apoptosis of gastric cancer cells by down regulating the expression of survivin.

Chun Yao1, Jinxiu Liu, Liwei Shao.   

Abstract

BACKGROUND/AIMS: Gastric cancer is the second cause of cancer death worldwide. The prognosis of gastric cancer is poor due to its aggressiveness and resistance to chemotherapy. It has been reported that mTOR signaling pathway plays an important role in the development of several cancers. Rapamycin is an inhibitor of mTOR signaling pathway. This study aimed to observe the effects of rapamycin on the proliferation, apoptosis and invasiveness in human gastric cancer cell lines, SGC-7901 and MKN-45, and its mechanisms. METHODOLGY: Different concentrations of rapamycin (5 nM, 10 nM, 20 nM and 40 nM) were used in our research. MTT and flow cytometry assays were used to detect the proliferation and apoptosis of SGC-7901 and MKN-45 cells. Transwell assay was used to observe the invasive ability of gastric cancer cells. To observe the mRNA and protein expression of mTOR and survivin, RT-PCR and western blot assays were used.
RESULTS: Our data showed that rapamycin could inhibit the proliferation and the invasive ability of SGC-7901 and MKN-45 cells. It also could induce the apoptosis of these two gastric cancer cell lines. These effects were observed in a dose dependent manner. The mRNA and protein expression of mTOR and survivin were inhibited by rapamycin as assessed by RT-PCR and western blot.
CONCLUSIONS: Rapamycin could inhibit the proliferation and the invasive ability and induce the apoptosis of human gastric cancer cells in vitro. It might exert its biological effects through the inhibition of mTOR and survivin.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21830446

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  11 in total

1.  Rapamycin induces the anti-apoptotic protein survivin in neuroblastoma.

Authors:  Ayman Samkari; Zachary A Cooper; Michael P Holloway; Jiebin Liu; Rachel A Altura
Journal:  Int J Biochem Mol Biol       Date:  2012-02-10

2.  Recombinant rubistatin (r-Rub), an MVD disintegrin, inhibits cell migration and proliferation, and is a strong apoptotic inducer of the human melanoma cell line SK-Mel-28.

Authors:  Clayton M Carey; Raymund Bueno; Daniel A Gutierrez; Christopher Petro; Sara E Lucena; Elda E Sanchez; Julio G Soto
Journal:  Toxicon       Date:  2011-12-13       Impact factor: 3.033

3.  Immunohistochemical expression of nuclear and cytoplasmic survivin in gastrointestinal carcinoma.

Authors:  Michiko Shintani; Akiko Sangawa; Naoki Yamao; Shingo Kamoshida
Journal:  Int J Clin Exp Pathol       Date:  2013-11-15

4.  Successful control of heavily pretreated metastatic gastric cancer with the mTOR inhibitor everolimus (RAD001) in a patient with PIK3CA mutation and pS6 overexpression.

Authors:  Ji Hyun Park; Min-Hee Ryu; Young Soo Park; Sook Ryun Park; Young-Soon Na; Baek-Yeol Rhoo; Yoon-Koo Kang
Journal:  BMC Cancer       Date:  2015-03-13       Impact factor: 4.430

5.  Lymphangiogenesis in gastric cancer regulated through Akt/mTOR-VEGF-C/VEGF-D axis.

Authors:  Hongxia Chen; Runnian Guan; Yupeng Lei; Jianyong Chen; Qi Ge; Xiaoshen Zhang; Ruoxu Dou; Hongyuan Chen; Hao Liu; Xiaolong Qi; Xiaodong Zhou; Changyan Chen
Journal:  BMC Cancer       Date:  2015-03-07       Impact factor: 4.430

6.  Amikacin Suppresses Human Breast Cancer Cell MDA-MB-231 Migration and Invasion.

Authors:  Yun-Hsin Wang; Yau-Hung Chen; Wen-Hao Shen
Journal:  Toxics       Date:  2020-11-20

7.  Synergistic effects of Rapamycin and Fluorouracil to treat a gastric tumor in a PTEN conditional deletion mouse model.

Authors:  Cong-Hui Zhu; Shuang-Qing Peng; Li-Li Cui; Wanying Cao; Li-Shi Zhang; Zeng-Ming Zhao; Li Jia; Ting-Fen Zhang; Jia-Bin Guo; Chengfang Pang
Journal:  Gastric Cancer       Date:  2021-08-09       Impact factor: 7.370

8.  Protective role of p70S6K in intestinal ischemia/reperfusion injury in mice.

Authors:  Kechen Ban; Rosemary A Kozar
Journal:  PLoS One       Date:  2012-07-27       Impact factor: 3.240

9.  Activation of SNAT1/SLC38A1 in human breast cancer: correlation with p-Akt overexpression.

Authors:  Kuo Wang; Fang Cao; Wenzheng Fang; Yongwei Hu; Ying Chen; Houzhong Ding; Guanzhen Yu
Journal:  BMC Cancer       Date:  2013-07-12       Impact factor: 4.430

Review 10.  Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence.

Authors:  Salihanur Darici; Hazem Alkhaldi; Gillian Horne; Heather G Jørgensen; Sandra Marmiroli; Xu Huang
Journal:  J Clin Med       Date:  2020-09-11       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.